<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Medical Wise &#187; Like</title>
	<atom:link href="http://mwcreative.com/tag/like/feed" rel="self" type="application/rss+xml" />
	<link>http://mwcreative.com</link>
	<description></description>
	<lastBuildDate>Sun, 08 Nov 2009 06:46:00 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>What Will Pfizer’s R&amp;D Look Like a Year from Now?</title>
		<link>http://mwcreative.com/what-will-pfizer%e2%80%99s-rd-look-like-a-year-from-now</link>
		<comments>http://mwcreative.com/what-will-pfizer%e2%80%99s-rd-look-like-a-year-from-now#comments</comments>
		<pubDate>Wed, 21 Oct 2009 16:28:40 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Research]]></category>
		<category><![CDATA[from]]></category>
		<category><![CDATA[Like]]></category>
		<category><![CDATA[Look]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[What]]></category>
		<category><![CDATA[Will]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://mwcreative.com/what-will-pfizer%e2%80%99s-rd-look-like-a-year-from-now</guid>
		<description><![CDATA[By Jonathan D. Rockoff
Pfizer&#8217;s huge R&#038;D shop is even bigger now that the company has swallowed Wyeth. To get a sense of the changes that could be in store, the Health Blog spoke today with the company&#8217;s two top R&#038;D execs &#8212; Martin Mackay, a Pfizer veteran who will lead small-molecule work, and Mikael Dolsten, [...]]]></description>
		<wfw:commentRss>http://mwcreative.com/what-will-pfizer%e2%80%99s-rd-look-like-a-year-from-now/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Other Drugmakers Want to Be More Like J&amp;J</title>
		<link>http://mwcreative.com/why-other-drugmakers-want-to-be-more-like-jj</link>
		<comments>http://mwcreative.com/why-other-drugmakers-want-to-be-more-like-jj#comments</comments>
		<pubDate>Mon, 12 Oct 2009 15:33:02 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Drugs]]></category>
		<category><![CDATA[Drugmakers]]></category>
		<category><![CDATA[Like]]></category>
		<category><![CDATA[More]]></category>
		<category><![CDATA[Other]]></category>
		<category><![CDATA[Want]]></category>

		<guid isPermaLink="false">http://mwcreative.com/why-other-drugmakers-want-to-be-more-like-jj</guid>
		<description><![CDATA[By Jacob Goldstein
Johnson &#038; Johnson&#8217;s third-quarter earnings, out today, provide the latest reminder of why other drugmakers want to be more like J&#038;J.
In a nutshell: It&#8217;s a tough time to be in the prescription drug business, what with stiff competition from generics manufacturers and payers pushing for lower costs on branded drugs. So it&#8217;s nice [...]]]></description>
		<wfw:commentRss>http://mwcreative.com/why-other-drugmakers-want-to-be-more-like-jj/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
